Skip to Navigation

Pipeline

Home > R & D > Pipeline

JWBS-R001

JWBS-R001

Novel biomarker for sepsis diagnosis

WRS (Tryptophanyl tRNA synthetase)

  • Novel biomarker for sepsis diagnosis
  • WRS is involved in innate immune response and is rapidly released into the blood during infection
  • Secreted level of WRS was increased in patients with sepsis caused by various types of infection (bacteria, fungi, viruses). WRS as a potential biomarker for sepsis diagnosis has been identified.
  • Will be approved by MFDS(Ministry of Food and Drug Safety) in 2020
  • Secreted tryptophanyl-tRNA synthetase as a primary defense system against infection (Ahn YH et al, Nature microbiology, 2016)

POCT (Point of care testing)

  • Rapid diagnostic platform for measuring biomarkers in blood
  • Automated analyzer based on CLEIA.​
  • Up to 6 tests per run in less than 20 minutes​
  • will be released in 2020

JWBS-R002

JWBS-R002

Novel biomarker for pancreatic cancer diagnosis

CFB (Complement factor B)

  • Novel biomarker for early diagnosis of pancreatic cancer
  • CFB is involved in the development and metastasis of pancreatic cancer and can be detected in the blood from the early stage of cancer. 
  • When combined with the existing pancreatic cancer biomarker CA19-9, CFB improves diagnostic accuracy of pancreatic cancer.
  • Underdeveloping CFB and CA19-9 multi-biomarker measurement kits and analysis algorithms. 
  • Identification of Human Complement Factor B as a Novel Biomarker Candidate for Pancreatic Ductal Adenocarcinoma (Lee et al, Journal of Proteome research, 2014)

POCT (Point of care testing)

  • Original technology patent registration (10-1594287)
  • Patent application status
    • US patent registered (15/347812)
    • Japanese patent registered (2016-567615)
    • European patent registered (14 892 029.1)
    • Chinese patent registered (201480078913.3)